Botulinum toxin vaccine - DynPort

Drug Profile

Botulinum toxin vaccine - DynPort

Alternative Names: Botulism vaccine - DynPort; rBV A/B; recombinant botulinum neurotoxin vaccine; Recombinant botulinum vaccine A/B

Latest Information Update: 05 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Bacterial vaccines
  • Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Botulism

Most Recent Events

  • 28 Aug 2015 Botulinium toxin vaccine is still in phase-II development for Botulism (Prevention) in USA
  • 12 Nov 2013 DynPort suspends enrolment in a phase III trial in healthy volunteers (in Botulism (prevention) in USA (NCT01940315)
  • 04 Apr 2008 Phase I development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top